

**Synthesis of Some Compounds of Activity against Some
Hormonal Disturbances and Analytical Study on Chosen
Examples from Compounds on the Market**

Thesis presented by

Essam Eldin Abdel Fattah Osman

B. Pharm. Sci.

Faculty of pharmacy, Cairo University

2000

Submitted in partial fulfillment for the Master Degree of Pharmaceutical Sciences
(Pharmaceutical Chemistry)

Supervised by

Prof. Dr. Hany Mohamed Safwat

Late professor of
pharmaceutical chemistry
Faculty of Pharmacy
Cairo University

Prof. Dr. Bahia Abbas Moussa

Professor of
pharmaceutical chemistry
Faculty of Pharmacy
Cairo University

Prof. Dr. Ramzia Ismail El-Bagary

Professor of pharmaceutical chemistry
Faculty of Pharmacy
Cairo University

Faculty of Pharmacy
Cairo University
2009

Approval Sheet

This thesis has been approved on by the examination committee.

Prof. Dr. Bahia Abbas Moussa

Professor of pharmaceutical chemistry

Faculty of Pharmacy, Cairo University

.....

Prof. Dr. Ramzia Ismail El-Bagary

Professor of pharmaceutical chemistry

Faculty of Pharmacy, Cairo University

.....

Prof. Dr. Safinaz El-Sayed Abbas

Professor of pharmaceutical chemistry

Faculty of Pharmacy, Cairo University

.....

Prof. Dr. Nawal Elrabbat

Professor of analytical chemistry

Faculty of Pharmacy, Assuit University

.....

Acknowledgement

First of all, I thank God for helping me to finish this work

I would like to express my sincere appreciation to Professor Dr. Hany Mohammed Safwat, late professor of pharmaceutical chemistry, faculty of pharmacy, Cairo University, for suggesting this point and being a source of knowledge we share today.

I am profoundly indebted to Professor Dr. Bahia Abbas Moussa, Professor of pharmaceutical chemistry, Faculty of Pharmacy, Cairo University for many days of unselfish work on my behalf, her support, concern and valuable supervision. It was a great honor working and learning under her guidance.

My deepest gratitude and cordial thanks goes to Professor Dr. Ramzia Ismail El-Bagary, Professor of pharmaceutical chemistry, Faculty of Pharmacy, Cairo University, for suggesting this work, frequent supervision, and generous encouragement through the whole study. From her I learned how to conduct a research and how a researcher should work, for that I shall be grateful forever.

Words of appreciation should extend to the members of my department at Faculty of Pharmacy, Cairo University for their support and friendly environment they created.

Finally, it is a pleasant duty to thank my parents, my wife, and all my colleagues for their support and prayers that always pushed me forward toward the completion of this work.

List of Abbreviations

AUP: Area under the peak
ASPEC: Automated Solid Phase Extraction Chromatography
K: Capacity factor
CE: Capillary electrophoresis
CV%: Coefficient of variance
C: Concentration
C_p max: Maximum concentration in plasma
R²: Correlation coefficient
CYP: Cytochrome P 450
ΔA: Difference absorbance
DSC: Differential scanning calorimetry technique
DBD: DNA binding domain
EIA: Enzyme immunoassay
ERα: Estrogen receptor alpha
ERβ: Estrogen receptor beta
ERE: Estrogen response elements
FID: Flame ionization detector
FDS: Frequency-doubling scattering
ΔG: Free energy of binding
GC: Gas chromatography
GnRH: Gonadotropin releasing hormone
HDL: High density lipoprotein
HPLC: High performance liquid chromatography
HRE: Hormone response element
Kcal/mol: Kilocalorie per mole
LBD: Ligand binding domain

LP: Lipoprotein
LOD: Limit of Detection
LOQ: Limit of Quantitation
LC: Liquid Chromatography
LLE: Liquid liquid extraction
LDL: Low density lipoprotein
MS: Mass spectrometry
M±SD: Mean ± standard deviation
MEKC: Micellar Electro Kinetic Chromatography
NO: Nitric Oxide
n: Number of experiments
N: Number of theoretical plates
ODS: Octadecylsiloxane
OVX: Ovary ectomized
PPM: Parts per million
PDB: Protein data bank
RRS: Resonance rayleigh scattering
RE%: Relative error %
RSD: Relative standard deviation
RP: Reversed phase
SERM: Selective estrogen receptor modulator
SAR: Structure activity relationship
SOS: Second-order scattering
SPE: Solid phase extraction
S.E: Standard error
SHBG: Sex hormone-binding globulin
t-test: Student's t-test

TCNQ: 7,7,8,8-Tetracyanoquinodimethane

TMS: Tetramethylsilane

TLC: Thin layer chromatography

TAF-1: Transcription activation factor 1

TAF-2: Transcription activation factor 2

TNF alpha: Tumor necrosis factor alpha

UV: Ultraviolet

USP-NF: United States Pharmacopeia – National Formulary

V: Variance

F-test: Variance ratio test

X: Mean

Contents

I. Introduction

I.1. General Introduction 1

I.2. Literature review

I.2.1. Literature review of the synthetic part 20

I.2.2. Literature review of the analytical part 42

II. Aim and basis of the present investigation 50

III. Experimental and discussion

III.1. Experimental and discussion of the synthetic part

III.1.1. Chemical synthesis

III.1.1.1. Synthesis of (Z/E) 1-(4-pyridyl)-1-phenyl-2-(p-substituted phenyl) ethylene (I) 56

III.1.1.2. Synthesis of (Z/E) 1-(2-pyridyl)-1-phenyl-2-(p-substituted phenyl) ethylene (II) 58

III.1.1.3. Synthesis of (Z/E) 3-[phenyl (2 or 4-pyridyl) methylene]-2-benzofuran-1(3*H*)-one (III) 60

III.1.1.4. Synthesis of (Z/E) phenyl (2 or 4-pyridyl) methanone phenylhydrazone (IV) 62

III.1.1.5. Synthesis of (Z/E) 2, 3-diphenyl-3-pyridin-4-ylacrylonitrile (V) 64

III.1.2. Pharmacological screening

III.1.2.1. Molecular modeling study 81

III.1.2.2. Assessment of estrogenicity 87

III.1.2.3. Measurement of potential cytotoxicity by SRB assay 89

III.2. Experimental and discussion of the analytical part

Drugs investigated in this thesis	107
General considerations	109
Materials	110
Chemical and reagents	110
Apparatus	110

III.2.1. Raloxifene hydrochloride methods

III.2.1.1. Determination of raloxifene hydrochloride by difference method (ΔA)

III.2.1.1.1. Principle	111
III.2.1.1.2. Determination of wavelength of the measurement	111
III.2.1.1.3. General procedure and linearity	113
III.2.1.1.4. Determination of raloxifene hydrochloride in bulk using difference method (ΔA)	115
III.2.1.1.5. Determination of raloxifene hydrochloride in Evista tablets using difference method (ΔA)	117

III.2.1.2. Spectrophotometric determination of raloxifene hydrochloride using TCNQ

III.2.1.2.1. Principle	119
III.2.1.2.2. Preparation of raloxifene base stock solution	119
III.2.1.2.3. Determination of the wavelength of maximum absorption	119
III.2.1.2.4.1. Effect of the amount of reagent	121
III.2.1.2.4.2. Effect of the reaction time	122
III.2.1.2.4.3. Stability of the color	123
III.2.1.2.4.4. Determination of the reaction stoichiometry	124

III.2.1.2.5. General procedure and linearity	125
III.2.1.2.6. Spectrophotometric determination of raloxifene hydrochloride in bulk using TCNQ	127
III.2.1.2.7. Spectrophotometric determination of raloxifene hydrochloride in Evista tablets using TCNQ	128

III.2.1.3. Spectrophotometric determination of raloxifene hydrochloride using Folin Ciocalteu's reagent

III.2.1.3.1. Principle	130
III.2.1.3.2. Preparation of raloxifene hydrochloride stock solution	130
III.2.1.3.3. Determination of the wavelength of maximum absorption	130
III.2.1.3.4.1. Effect of the amount of the reagent	132
III.2.1.3.4.2. Effect of the amount of 10% Na ₂ CO ₃ added	133
III.2.1.3.4.3. Effect of the reaction time	134
III.2.1.3.4.4. Stability of the color	135
III.2.1.3.5. General procedure and linearity	136
III.2.1.3.6. Spectrophotometric determination of raloxifene hydrochloride in bulk using Folin Ciocalteu's reagent	138
III.2.1.3.7. Spectrophotometric determination of raloxifene hydrochloride in Evista tablets using Folin Ciocalteu's reagent	140

III.2.1.4. RP- High performance liquid chromatographic determination of raloxifene hydrochloride

III.2.1.4.1. Principle	141
III.2.1.4.2. Preparation of raloxifene hydrochloride stock solution	141
III.2.1.4.3. Preparation of benzophenone stock solution	141

III.2.1.4.4. Mobile phase	141
III.2.1.4.5. Preparation of the system	141
III.2.1.4.6. General procedure and linearity	142
III.2.1.4.7. Determination of raloxifene hydrochloride in bulk using RP- HPLC method	144
III.2.1.4.8. Determination of raloxifene hydrochloride in Evista tablets using RP- HPLC method	146

Discussion of raloxifene hydrochloride methods:

III.2.1.1. Spectrophotometric determination of raloxifene hydrochloride using difference method (ΔA)	148
III.2.1.2. Spectrophotometric determination of raloxifene hydrochloride using 7,7,8,8-tetracyanoquinodimethane (TCNQ)	149
III.2.1.3. Spectrophotometric determination of raloxifene hydrochloride using Folin Ciocalteu's reagent	153
III.2.1.4. Reversed phase high performance liquid chromatographic method for determination of raloxifene hydrochloride	156

III.2.2. Letrozole methods

III.2.2.1. Spectrofluorometric determination of letrozole

III.2.2.1.1. Principle	160
III.2.2.1.2. Preparation of letrozole stock solution	160
III.2.2.1.3. Determination of the wavelength of maximum emission	160
III.2.2.1.4. General procedure and linearity	161
III.2.2.1.5. Spectrofluorometric determination of letrozole in bulk	163
III.2.2.1.6. Spectrofluorometric determination of letrozole in Femara tablets ...	164

III.2.2.2. RP- High performance liquid chromatographic determination of letrozole

III.2.2.2.1. Principle	166
III.2.2.2.2. Preparation of letrozole stock solution	166
III.2.2.2.3. Preparation of benzophenone stock solution	166
III.2.2.2.4. Mobile phase	166
III.2.2.2.5. Preparation of the system	167
III.2.2.2.6. General procedure and linearity	167
III.2.2.2.7. Determination of letrozole in bulk by RP-HPLC	169
III.2.2.2.8. Determination of letrozole in Femara tablets using RP-HPLC method	171

III.2.2.3. RP- High performance liquid chromatographic determination of letrozole in serum

III.2.2.3.1. Principle	173
III.2.2.3.2. Preparation of letrozole stock solution	173
III.2.2.3.3. Mobile phase	173
III.2.2.3.4. Preparation of the system	173
III.2.2.3.5. General procedure and linearity	174
III.2.2.3.6. Determination of letrozole in bulk	176

Discussion of letrozole methods

III.2.2.1. Spectrofluorometric determination of Letrozole	178
III.2.2.2. Reversed phase high performance liquid chromatographic method for determination of letrozole	179
III.2.2.3. Reversed phase high performance liquid chromatographic method for determination of letrozole in serum	181

IV. English summary	185
V. References	189
VI. Arabic summary	

List of tables

Table no.	Title	Page
1	Some currently approved drugs for female hormonal disturbances	19
2	Micro analytical data of series (I)	57
3	IR bands of some compounds in series (I)	57
4	Micro analytical data of series (II)	59
5	IR and mass data of some compounds in series (II)	59
6	Micro analytical data of series (III)	60
7	IR and mass data of series (III)	61
8	Micro analytical data of series (IV)	62
9	IR and mass data of series (IV)	63
10	Micro analytical data of compound (V)	64
11	Estrogen Receptor Summary	83
12	Summary of docking results of the tested compounds	84
13	Results of the immature rat uterine assay	88
14	Surviving fraction of MCF-7 for compound (I.1)	90
15	Surviving fraction of MCF-7 for compound (I.2)	91
16	Surviving fraction of MCF-7 for compound (I.3)	92
17	Surviving fraction of MCF-7 for compound (I.4)	93
18	Surviving fraction of MCF-7 for compound (II.1)	94
19	Surviving fraction of MCF-7 for compound (II.2)	95
20	Surviving fraction of MCF-7 for compound (II.3)	96
21	Surviving fraction of MCF-7 for compound (II.4)	97
22	Surviving fraction of MCF-7 for compound (III.1)	98
23	Surviving fraction of MCF-7 for compound (III.2)	99

24	Surviving fraction of MCF-7 for compound (IV.1)	100
25	Surviving fraction of MCF-7 for compound (IV.2)	102
26	Surviving fraction of MCF-7 for compound (V)	103
27	Surviving fraction of MCF-7 for doxorubicin	104
28	Surviving fraction of MCF-7 for tamoxifen	105
29	Comparison of the pharmacological screening results	106
30	Determination of raloxifene hydrochloride in bulk using difference method (ΔA)	116
31	Determination of raloxifene hydrochloride in Evista tablets using difference method (ΔA)	118
32	Effect of the amount of TCNQ in the determination of raloxifene hydrochloride using TCNQ	121
33	Effect of the reaction time in the determination of raloxifene hydrochloride using TCNQ	122
34	Stability of the color in the determination of raloxifene hydrochloride using TCNQ	123
35	Spectrophotometric determination of raloxifene hydrochloride in bulk using TCNQ	127
36	Spectrophotometric determination of raloxifene hydrochloride in Evista tablets using TCNQ	129
37	Effect of the amount of Folin Ciocalteu's reagent in the determination of raloxifene hydrochloride	132
38	Effect of the amount of 10% Na_2CO_3 in the determination of raloxifene hydrochloride using Folin Ciocalteu's reagent	133
39	Effect of the reaction time in the determination of raloxifene hydrochloride using Folin Ciocalteu's reagent	134

40	Stability of the color in the determination of raloxifene hydrochloride using Folin Ciocalteu's reagent	135
41	Spectrophotometric determination of raloxifene hydrochloride in bulk using Folin Ciocalteu's reagent	138
42	Spectrophotometric determination of raloxifene hydrochloride in Evista tablets using Folin Ciocalteu's reagent	140
43	Determination of raloxifene hydrochloride in bulk using RP-HPLC	145
44	Determination of raloxifene hydrochloride in Evista tablets using RP-HPLC	147
45	Statistical analysis for the methods used in the quantitative determination of raloxifene hydrochloride	158
46	Intra-and inter-day validation for the determination of raloxifene hydrochloride by RP-HPLC method	159
47	Spectrofluorometric determination of letrozole in bulk	163
48	Spectrofluorometric determination of letrozole in Femara tablets	165
49	Determination of letrozole in bulk using RP-HPLC	170
50	Determination of letrozole in Femara tablets using RP-HPLC method	172
51	Determination of letrozole in serum using RP-HPLC	177
52	Statistical analysis of the methods used in the determination of letrozole	183
53	Intra-and inter-day validation for the determination of letrozole by RP-HPLC method	184
54	Intra-and inter-day validation for the determination of letrozole	